Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer

NCT ID: NCT00521937

Last Updated: 2010-12-15

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 388 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-01-31
• Study Completion Date: 2010-12-31

Brief Summary

It is estimated that 300 million people worldwide will have diabetes by the year 2025. About 12 percent of those with diabetes will have had a foot ulcer, which is a major source of morbidity, concern, and cost.

The foot ulcers are the leading cause of hospitalization among people with diabetes and often lead to amputation. The costs of treatment and the high morbidity and mortality associated with diabetic foot problems necessitate the need for a systemic approach to a foot ulcer management.

Current local treatments of this type of ulcer are: dressings (hydrocolloids, alginate…), and growth factors. However modern dressings may not avoid infection and the results of the clinical studies are not significant in terms of complete healing rate or in terms of time to healing. Concerning growth factors, the only one whose therapeutic application made proof is the rhPDGF (Regranex®) with an increase in the number of ulcers completely healed at the twentieth week compared to placebo (50% and 35%, respectively).

The advancement of tissue-engineering has made possible dermal replacement on human wounds to facilitate healing.

A new sponge composed of collagen and glycosaminoglycans (chondroitins 4 and 6 sulphate), reticulated by ionic bonds with chitosan before freeze-drying, was developed in France. This sponge is a non-toxic product due to its non-chemical reticulation (ionic bonds), biocompatible and biodegradable processes, handling and storable easily.

The objective of this study is to demonstrate that such a substitute, cellularized by functional allogenic fibroblasts, and complying with all safety conditions, enables to lead to healing of diabetic foot ulcers.

Conditions

Diabetes; Foot Ulcer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

A

Dermagen®

Group Type: EXPERIMENTAL

Dermagen®

Intervention Type: OTHER

Weekly topical applications

B

Conventional treatment

Group Type: ACTIVE_COMPARATOR

Dermagen®

Intervention Type: OTHER

Weekly topical applications

Interventions

Dermagen®

Weekly topical applications

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Female or male patient aged ≥ 18
• Patient with documented and stable* type I or II diabetes mellitus
• With diagnosis of neuropathic foot ulcer located on the plantar surface of the forefoot
• Ulcer with a surface area comprised between 1 and 15 cm2 included (after mechanical debridement of the ulcer)
• Palpable pulse evidenced on both feet (presence of dorsalis pedis pulse and posterior tibial pulse) or in absence of one pulse, a Systolic Pressure Index (SPI) by Doppler > 0.9 on the target limb
• Presence of diabetic foot ulcer for at least 4 weeks prior to enrolment
• Patient's ulcer extending through the dermis without exposure of muscle, tendon, bone, or joint capsule *means confirmed by HbA1C at least every 4 months

Exclusion Criteria

• Typical Charcot's foot
• Decrease or increase in the size of the ulcer by 50% or more during the run-in period
• Presence of osteitis (eq Br osteomyelitis) at the inclusion visit (evidenced with a radiological lesion facing the wound (bone erosion or disappearance of the cortical bone))
• Clinical evidence of Pedis grade 3, or 4 infection at the inclusion visit
• Patient who cannot have an off-loading method
• Patient with working activity who cannot be on sick-leave during the study period.
• Patient presenting a known allergy to collagen, streptomycin, penicillin and/or products of bovine origin
• Dialysed patient
• Patient suffering from a psychiatric disorder not treated
• Clinical evidence of gangrene on any part of the affected foot
• Patient receiving corticosteroids, NSAIDs, immunosuppressive or cytotoxic agents, all systemic agents that can affect wound repair or any treatment that might interfere with the assessment of the study treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Laboratoires Genévrier

INDUSTRY

Sponsor Role: lead

Responsible Party

Laboratoires Genevrier

Principal Investigators

Olivier Chosidow, MD, PhD

Role: STUDY_CHAIR

Hôpital Tenon, Paris

Locations

Marseille, , France

Nancy, , France

Nîmes, , France

Paris, , France

Roubaix, , France

Thionville, , France

Toulouse, , France

Countries

France

Other Identifiers

06FB/DE02

Identifier Type: -

Identifier Source: org_study_id